Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors.

Journal of Immunotherapy
Pankaj AgarwallaWilliam T Curry

Abstract

Malignant glioma is an incurable disease with a relatively short median survival. Several clinical trials have demonstrated that immunotherapy with vaccination is a safe and possibly effective way of prolonging survival. Antibody-based blockade of cytotoxic T-lymphocyte antigen 4 (CTLA-4) ligation on T lymphocytes is associated with enhanced antitumor immunity in animal models of cancer and in patients with advanced melanoma. We hypothesized that sequential therapy with granulocyte-macrophage-colony-stimulating factor (GM-CSF)-expressing whole-glioma-cell vaccination and CTLA-4 blockade is an effective strategy for treating established intracranial gliomas. GL261 glioma cells were injected into the right frontal lobes of syngeneic C57/BL6 mice. At days 3, 6, and 9 after tumor implantation, mice were treated with subcutaneous injection of irradiated GM-CSF-expressing GL261 cells. Mice were also treated with intraperitoneal injection of anti-CTLA-4 monoclonal antibodies (mAbs), either at days 3, 6, and 9 or days 12, 15, and 18. Animals were followed for survival. Splenocytes were harvested at day 22 for use in enzyme-linked immunosorbent spot assays. Early treatment of established intracranial gliomas with high-dose CTLA-4 blocka...Continue Reading

References

Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Aug 3, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Linda M LiauMichael D Roth
Jun 17, 2006·The Journal of Clinical Investigation·Sergio A QuezadaJames P Allison
Apr 4, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Peter E FecciJohn H Sampson
Feb 22, 2008·Proceedings of the National Academy of Sciences of the United States of America·F Stephen HodiGlenn Dranoff
Aug 21, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Casey A MaguireMiguel Sena-Esteves
Dec 1, 2009·Neurosurgery Clinics of North America·Emilia AlbesianoMichael Lim
Dec 1, 2009·Neurosurgery Clinics of North America·Allen Waziri
Dec 1, 2009·Neurosurgery Clinics of North America·Gordon LiAlbert J Wong
Dec 1, 2009·Neurosurgery Clinics of North America·Won Kim, Linda M Liau
Dec 1, 2009·Neurosurgery Clinics of North America·Pankaj K AgarwallaWilliam T Curry
Jun 17, 2010·Journal of Immunotherapy·Sanjiv S Agarwala, Antoni Ribas
Sep 8, 2010·The New England Journal of Medicine·Philip W KantoffUNKNOWN IMPACT Study Investigators
Oct 6, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John H SampsonDarell D Bigner
Nov 16, 2010·Seminars in Oncology·Kim A MargolinMichele Maio
Dec 2, 2010·Cancer Immunology, Immunotherapy : CII·Wim Maes, Stefaan W Van Gool

❮ Previous
Next ❯

Citations

Oct 20, 2012·Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.]·Andrea BaloghKatalin Lumniczky
Jun 12, 2013·Biochimica Et Biophysica Acta·Simone Mocellin, Donato Nitti
Jul 11, 2014·Journal of Immunology Research·Dong-Sup ChungYong-Kil Hong
Jul 22, 2014·Immunotherapy·Robert L Bowman, Johanna A Joyce
Sep 1, 2014·Seminars in Oncology·Patrick C GedeonJohn H Sampson
Jun 15, 2014·Journal of Cancer Research and Clinical Oncology·Yuli LiYuquan Wei
Nov 28, 2013·The Journal of Experimental Medicine·Johannes Vom BergBurkhard Becher
Jul 30, 2016·Oncoimmunology·Tiffany R HodgesAmy B Heimberger
Feb 18, 2016·Journal of Immunology Research·Eileen S KimMichael Lim
Oct 12, 2015·Current Treatment Options in Oncology·Martha R Neagu, David A Reardon
Nov 19, 2013·International Journal of Cancer. Journal International Du Cancer·Sofia EberstålPeter Siesjö
Nov 26, 2015·Immunotherapy·Anda-Alexandra CalinescuMaria Graciela Castro
Sep 1, 2015·Seminars in Oncology·Joseph ObeidCraig L Slingluff
Mar 10, 2015·Journal of Neuro-oncology·Jennifer E Kim, Michael Lim
Feb 18, 2015·Frontiers in Oncology·Leonel AmpieChristopher Dardis
Jun 3, 2016·Expert Review of Anticancer Therapy·Nicole A P LiebermanCourtney A Crane
Jul 14, 2016·Expert Opinion on Biological Therapy·Neha KamranMaria G Castro
Oct 31, 2015·Neuro-oncology·William T Curry, Michael Lim
Dec 22, 2016·Immunotherapy·Shunichiro KuramitsuAtsushi Natsume
Jan 24, 2017·Annales de pathologie·Emilie De CarliAudrey Rousseau
Mar 14, 2017·Expert Opinion on Biological Therapy·Mayuri ChandranMaria G Castro
Mar 18, 2017·Current Oncology Reports·Aaron C TanMustafa Khasraw
Mar 17, 2017·World Neurosurgery·Alice L HungMichael Lim
Apr 4, 2017·Current Opinion in Neurology·David A ReardonJohn H Sampson
May 13, 2017·Nature Reviews. Neurology·Michael WellerJohn H Sampson
Jun 24, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John H SampsonCarl H June
Nov 28, 2012·Nature Reviews. Clinical Oncology·Shota TanakaJorg Dietrich
Feb 10, 2018·Immunotherapy·Neha KamranMaria G Castro
Feb 7, 2018·Therapeutic Advances in Neurological Disorders·Alberto PiccaMarc Sanson
Feb 14, 2020·Journal for Immunotherapy of Cancer·William James KellyMark Gilbert
Jun 2, 2018·Oncotarget·Malaka AmeratungaJuanita Lopez
Oct 21, 2016·Oncotarget·Xuhao ZhangJingtao Chen
Jun 12, 2013·Expert Review of Vaccines·David A ReardonGlenn Dranoff
Nov 10, 2013·Cancers·Brian J AhnHideho Okada

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.